» Authors » Omar Albanyan

Omar Albanyan

Explore the profile of Omar Albanyan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 46
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, et al.
Transplant Cell Ther . 2024 Aug; 30(11):1090.e1-1090.e10. PMID: 39147136
Fludarabine (Flu) and melphalan (Mel) reduced-intensity conditioning is frequently used for allogenic hematopoietic cell transplant (allo-HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, there is...
2.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bucklein V, Volkl S, et al.
Sci Adv . 2023 Sep; 9(38):eadg3919. PMID: 37738350
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how (CAR) T cell expansion...
3.
Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al.
Am J Hematol . 2023 Aug; 98(11):1699-1710. PMID: 37584447
CD19-directed CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel) has substantially improved treatment outcomes for patients with relapsed/refractory mantle cell lymphoma (r/r MCL). Prolonged cytopenias and infections represent common and clinically...
4.
Bucklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, et al.
Hemasphere . 2023 Jul; 7(8):e907. PMID: 37449196
Real-world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient- and disease-related...
5.
Albanyan O, Chavez J, Munoz J
Ther Adv Hematol . 2022 Dec; 13:20406207221141511. PMID: 36505886
For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach...
6.
Crowder S, Sauls R, Redwine L, Nieder M, Albanyan O, Yasin H, et al.
Cancers (Basel) . 2022 Jun; 14(11). PMID: 35681740
Previous adolescent and young adult (AYA) research suggests patients undergoing hematopoietic stem cell transplantation (HSCT) experience severe physiological stress. The goal of this study was to identify unmet needs, interests,...
7.
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, et al.
Hematol Oncol Stem Cell Ther . 2021 Aug; 16(2):154-157. PMID: 34425096
Mantle cell lymphoma is a rare subtype of non-Hodgkin's lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic...
8.
Modi D, Albanyan O, Kim S, Deol A, Ayash L, Ratanatharathorn V, et al.
Leuk Lymphoma . 2021 Feb; 62(8):1982-1989. PMID: 33627028
The information on the impact of cytokine release syndrome (CRS) on haploidentical donor peripheral blood stem cell transplant (haploPBSCT) outcomes is limited. We retrospectively evaluated 98 patients who underwent haploPBSCT...
9.
Zaiem F, Jerbi R, Albanyan O, Puccio J, Kafri Z, Yang J, et al.
Avicenna J Med . 2021 Jan; 10(4):241-248. PMID: 33437697
Background: CD10, BCL6, and MUM1 are commonly used immunohistochemical stains for classifying diffuse large B-cell lymphoma (DLBCL), which is useful in predicting outcome. Conflicting reports of the prognostic value of...